St. Jude Medical Announces CE Mark Approval Of The World's Only MultiPoint Pacing Pacemaker
St. Jude Medical, Inc., a global medical device company, recently announced CE Mark approval of the Quadra Allure MP cardiac resynchronization therapy pacemaker (CRT-P). (Source: Medical Design Online News)
Source: Medical Design Online News - December 15, 2014 Category: Medical Equipment Source Type: news

Medtronic Receives FDA Approval And Launches Two New Cardiac Resynchronization Therapy Quadripolar Leads
Medtronic, Inc. recently announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of two additional Attain Performa left ventricular (LV) quadripolar leads, which can be paired with the Medtronic Viva Quad XT and Viva Quad S cardiac resynchronization therapy defibrillators (CRT-D) to treat patients with heart failure. (Source: Medical Design Online News)
Source: Medical Design Online News - December 12, 2014 Category: Medical Equipment Source Type: news

Medtronic wins FDA approval for more Attain Performa quad defib leads
Medtronic says it won pre-market approval from the FDA for another pair of Attain Performa quadripolar cardiac resynchronization therapy defibrillator leads. Food & Drug Administration (FDA), MedtronicNews Well, Cardiac Rhythm Management, Pre-Market Approval (PMA), Regulatory/Complianceread more (Source: Mass Device)
Source: Mass Device - December 11, 2014 Category: Medical Equipment Authors: Brad Perriello Source Type: news

St. Jude Medical wins CE Mark for Quadra Allure MP pacemaker
St. Jude Medical says it won CE Mark approval in the European Union for its Quadra Allure MP pacemaker, claiming it as the sole cardiac resynchronization therapy pacemaker to offer multi-point pacing. St. Jude MedicalNews Well, Cardiac Rhythm Management, CE Markread more (Source: Mass Device)
Source: Mass Device - December 11, 2014 Category: Medical Equipment Authors: Brad Perriello Source Type: news

Medtronic touts CRT data
Meta-analyses of Medtronic-sponsored studies show the clinical and economic benefits of its cardiac resynchronization therapy devices. Medtronic (NYSE:MDT) yesterday touted the results of meta-analyses of a group of company-sponsored studies of its cardiac resynchronization therapy devices, saying the data show the clinical and economic value its CRT portfolio. MedtronicNews Well, Cardiac Rhythm Managementread more (Source: Mass Device)
Source: Mass Device - November 17, 2014 Category: Medical Equipment Authors: Brad Perriello Source Type: news

ESC: Quadripolar Tops Bipolar in Cardiac Pacing (CME/CE)
BARCELONA (MedPage Today) -- Quadripolar left ventricle lead technology dramatically reduced perioperative complications in implanting cardiac pacemakers for cardiac resynchronization therapy, researchers reported here. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 31, 2014 Category: Cardiology Source Type: news

Medtronic launches personalized heart rhythm therapy trial
Medtech titan Medtronic enrolls the 1st patients in the AdaptResponse clinical trial to evaluate its adaptive cardiac rhythm management technology. Medtronic (NYSE:MDT) touted the launch of its AdaptResponse trial, the largest study of its kind evaluating the company's AdaptivCRT algorithm for personalizing cardiac resynchronization therapy in treatment of heart failure. MedtronicNews Well, Clinical Trials, Cardiac Implants, Cardiac Rhythm Management, Implants, Minnesotaread more (Source: Mass Device)
Source: Mass Device - August 27, 2014 Category: Medical Equipment Authors: Arezu Sarvestani Source Type: news

Medtronic's personalized pacemaker wins FDA approval
FDA regulators approve Medtronic's new Viva CRT-P adaptive cardiac pacemaker for treatment of heart failure or atrioventricular block. Medtronic (NYSE:MDT) won FDA approval for its Viva CRT-P cardiac resynchronization therapy-pacemaker, which features proprietary software to adjust its pacing parameters to a patient's heart rhythms minute-by-minute. MedtronicNews Well, Regulatory/Clearance, Cardiac Rhythm Management, Food & Drug Administration (FDA), Minnesota, Pre-Market Approval (PMA)read more (Source: Mass Device)
Source: Mass Device - August 25, 2014 Category: Medical Equipment Authors: Arezu Sarvestani Source Type: news

Press Release: Medtronic Viva cardiac resynchronization therapy-pacemaker now available in U.S.
AdaptivCRT algorithm customizes therapy for heart failure patients and improves their response rates. MINNEAPOLIS - Medtronic, Inc. (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval of its newest cardiac resynchronization therapy-pacemaker, Viva® CRT-P, for indicated patients with heart failure or atrioventricular (AV) block. MedtronicNews Well, Press Release, Regulatory/Clearance, Cardiac Rhythm Management, Food & Drug Administration (FDA), Minnesota, Pre-Market Approval (PMA)read more (Source: Mass Device)
Source: Mass Device - August 25, 2014 Category: Medical Equipment Authors: MassDevice Source Type: news

Implantable heart devices result in similar survival benefits among ethnic, racial groups
Racial and ethnic minorities who receive implantable devices to treat heart failure derive the same substantial survival benefit from these therapies as white patients, new UCLA-led research shows. While the American College of Cardiology and American Heart Association jointly recommend the use of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT) devices for all eligible patients, minorities have not been well represented in clinical trials of the devices, and previous studies had shown that African American and Hispanic patients are less likely to receive these recommended therapie...
Source: UCLA Newsroom: Health Sciences - August 18, 2014 Category: Universities & Medical Training Source Type: news

Medtronic Receives FDA Approval For Attain Performa Quadripolar Lead And Viva Quad CRT-Ds In United States
Medtronic, Inc. recently announced it has received United States Food and Drug Administration (FDA) approval for the Attain Performa Model 4298 quadripolar lead, and the Viva Quad XT and Viva Quad S cardiac resynchronization therapy defibrillators (CRT-D). (Source: Medical Design Online News)
Source: Medical Design Online News - August 11, 2014 Category: Medical Equipment Source Type: news

Medtronic brings new smart pacemaker to India | MassDevice.com On Call
Medtech titan Medtronic launched a new cardiac resynchronization therapy-pacemaker for the Indian market after landing CE Mark approval in the European Union earlier this year. MASSDEVICE ON CALL — Medtronic (NYSE:MDT) this week announced that it's bringing its Viva cardiac resynchronization therapy-pacemaker to the market in India, a country where Medtronic is banking on significant growth. MedtronicNews Well, Emerging Markets, On Call, Cardiac Rhythm Management, Minnesotaread more (Source: Mass Device)
Source: Mass Device - August 8, 2014 Category: Medical Equipment Authors: Arezu Sarvestani Source Type: news

Press Release: Medtronic receives FDA approval for attain Performa Quadripolar lead and Viva Quad CRT-Ds in United States
New system helps physicians deliver cardiac resynchronization therapy optimally and efficiently to heart failure patients. MedtronicPress Release, Regulatory/Clearance, Cardiac Rhythm Management, Food & Drug Administration (FDA), Minnesota, Pre-Market Approval (PMA)read more (Source: Mass Device)
Source: Mass Device - August 8, 2014 Category: Medical Equipment Authors: MassDevice Source Type: news

QRS-Based CRT Advantage for Women in Mild HF: Meta-AnalysisQRS-Based CRT Advantage for Women in Mild HF: Meta-Analysis
Survival went up significantly from cardiac resynchronization therapy across a wider range of QRS durations in women compared with men, with implications for gender-based guidelines. Heartwire (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 27, 2014 Category: Consumer Health News Tags: Cardiology News Source Type: news

Women Helped by CRT More Than Men
(MedPage Today) -- Among patients with left bundle branch block (LBBB) and mild heart failure, women derive a benefit from cardiac resynchronization therapy (CRT) at shorter QRS durations compared with men, an FDA analysis showed. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - June 23, 2014 Category: Consumer Health News Source Type: news

EHRA White Book 2014 highlights growing use of complex therapies for heart rhythm abnormalities
(European Society of Cardiology) The White Book contains data on the use of cardiovascular implantable electronic devices including pacemakers, implantable cardiac defibrillators, cardiac resynchronization therapy devices, and lead extractions procedures in Europe. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 17, 2014 Category: Global & Universal Source Type: news

Consumer Information on: Medtronic CRT-D Devices - P010031S381
A Cardiac Resynchronization Therapy (CRT) device is a special pacemaker designed to treat symptoms of heart failure by sending specially timed electrical impulses to improve the timing, or resynchronize pumping action of the heart's lower chambers (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - May 9, 2014 Category: Medical Equipment Source Type: news

Consumer Information on: Medtronic CRT-P Devices - P010015S205
A Cardiac Resynchronization Therapy (CRT) device is a special pacemaker designed to treat symptoms of heart failure by sending specially timed electrical impulses to improve the timing, or resynchronize pumping action of the heart's lower chambers (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - May 9, 2014 Category: Medical Equipment Source Type: news

Medtronic Viva Cardiac Resynchronization Therapy-Pacemaker Now Available In Europe
Medtronic, Inc. recently announced CE (Conformité Européenne) Mark receipt and the European launch of its newest cardiac resynchronization therapy-pacemaker, Viva CRT-P. The Viva CRT-P is not approved for sale in the United States. (Source: Medical Design Online News)
Source: Medical Design Online News - May 2, 2014 Category: Medical Equipment Source Type: news

Medtronic wins E.U. approval for adaptive, diagnostic Viva pacemaker
Medtronic launches European sales of its Viva CRT-P, which self-adjusts to adapt to patients' heart rhythms and provides diagnostic insight into a patient's physiology. Minnesota medtech titan Medtronic (NYSE:MDT) launched European sales of its Viva cardiac resynchronization therapy-pacemaker after landing a win from overseas regulators. MedtronicNews Well, Regulatory/Clearance, Cardiac Rhythm Management, CE Mark, Minnesotaread more (Source: Mass Device)
Source: Mass Device - May 1, 2014 Category: Medical Equipment Authors: Arezu Sarvestani Source Type: news

IN-TIME analysis reveals equal telemonitoring benefits for ICD and CRT-D devices
Heart failure patients receive similar benefits from implantable devices fitted with telemonitoring technology alerting medical experts to problems regardless of whether they are fitted with cardioverter defibrillators (ICD) or cardiac resynchronization therapy defibrillators (CRT-D), reported the latest analysis of the IN-TIME trial in yesterday’s Late Breaking Trial session. Topics: Heart Failure (HF) (Source: ESC News and Press)
Source: ESC News and Press - April 23, 2014 Category: Cardiology Source Type: news

Medtronic CRT Devices Now Approved To Treat Patients With AV Block And Reduced Heart Function
Medtronic, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for biventricular (BiV) pacing with Medtronic cardiac resynchronization therapy-pacemakers and -defibrillators (CRT-P and CRT-D). (Source: Medical Design Online News)
Source: Medical Design Online News - April 17, 2014 Category: Medical Equipment Source Type: news

FDA Clears CRT Devices for More HF Patients
(MedPage Today) -- The FDA has expanded the indication for several cardiac resynchronization therapy devices made by Medtronic to include patients with atrioventricular block and milder heart failure. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 11, 2014 Category: Cardiology Source Type: news

ACC 2014 Roundup: Study shows long-term benefits for some CRT-D patients
Seven-year results from Boston Scientific's MADIT-CRT trial show long-term benefits for some patients with mild heart failure. Some patients with mild heart failure show significant, long-term benefits from cardiac-resynchronization therapy, according to the 7-year results from Boston Scientific's (NYSE:BSX) MADIT-CRT clinical trial presented at the American College of Cardiology's annual meeting over the weekend. American College of Cardiology, Boston Scientific, Abbott LaboratoriesNews Well, Clinical Trials, ACC 2014, Bariatrics, Diabetes, Replacement Heart Valves, Stent Warsread more (Source: Mass Device)
Source: Mass Device - March 31, 2014 Category: Medical Equipment Authors: Brad Perriello Source Type: news

Cardiac resynchronization improves survival in heart failure patients
Patients in mild heart failure who receive a specialized pacemaker known as cardiac resynchronization therapy with a defibrillator may live longer than those implanted with a traditional implantable cardioverter defibrillator, according to research. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 31, 2014 Category: Science Source Type: news

Survival Benefit Found After Long-Term Resynchronization Therapy
MADIT-CRT was an influential trial that showed a reduction in heart failure complications — but not mortality — when cardiac resynchronization therapy (CRT) was added to an implantable defibrillator in patients with mild heart failure who also had left bundle-branch block (LBBB). Patients in the trial were followed for 2.4 years, raising questions about the long-term effects of CRT. Now, a second look at 854 patients who participated in a follow-up study, presented at the American College of Cardiology and published in the New England Journal of Medicine, suggests that over the long ter...
Source: Forbes.com Healthcare News - March 30, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

Three New St. Jude Pacemakers Cleared For U.S. Market
St. Jude Medical announced earlier this week that the FDA has granted approval for the Allure Quadra Cardiac Resynchronization Therapy Pacemaker (CRT-P), along with the Assurity and Endurity families of pacemakers. (Source: Medical Design Online News)
Source: Medical Design Online News - March 26, 2014 Category: Medical Equipment Source Type: news

Study: Algorithm uses activity, breathing data to predict heart failure events
A non-randomized, double-blind study of 521 patients with heart failure found that the combination of data from minute ventilation and physical activity sensors could predict 34 percent of heart failure events, according to a study published in the European Journal of Heart Failure. “Monitoring early signs of clinical deterioration could allow physicians to adjust medical treatment [...] (Source: mobihealthnews)
Source: mobihealthnews - March 24, 2014 Category: Information Technology Authors: Aditi Pai Tags: Uncategorized activity sensors cardiac resynchronization therapy defibrillation devices European Journal of Heart Failure minute ventilation Physiological Diagnostic Source Type: news

St. Jude Medical's Allure Quadra pacemaker wins FDA OK
The FDA grants pre-market approval to St. Jude Medical's Allure Quadra cardiac resynchronization therapy pacemaker. St. Jude Medical (NYSE:STJ) said its Allure Quadra pacemaker will be the 1st on the U.S. market to offer quadripolar cardiac resynchronization therapy after the FDA granted pre-market approval to the device. Food & Drug Administration (FDA), St. Jude MedicalNews Well, Cardiac Rhythm Management, Pre-Market Approval (PMA), Regulatory/Complianceread more (Source: Mass Device)
Source: Mass Device - March 24, 2014 Category: Medical Equipment Authors: Brad Perriello Source Type: news

Biotronik inks VA deal
Biotronik will provide cardiac rhythm management devices for U.S. military veterans via the Veterans Affairs Administration. Biotronik said it inked a deal to provide cardiac rhythm management devices to the 8 million veterans served by the U.S. Veterans Affairs Dept. The Berlin-based company makes cardiac resynchronization therapy defibrillators and endovascular medical devices. News Well, Cardiac Rhythm Management, Deals Roundupread more (Source: Mass Device)
Source: Mass Device - January 10, 2014 Category: Medical Equipment Authors: Chris Walker Tags: Biotronik U.S. Veteran Affairs Dept. Source Type: news

Boston Scientific Announces CE Mark Approval And First Implants Of Its Next-Generation X4 Quadripolar CRT-D Systems
Boston Scientific Corporation (NYSE:BSX) has received CE Mark approval of its X4 line of quadripolar CRT-D systems, including the AUTOGEN™ X4, DYNAGEN™ X4, and INOGEN™ X4 cardiac resynchronization therapy defibrillators (CRT-Ds), a suite of ACUITY™ X4 quadripolar LV leads and the ACUITY™ PRO lead delivery system. (Source: Medical Design Online News)
Source: Medical Design Online News - December 19, 2013 Category: Medical Equipment Source Type: news

Johns Hopkins Researchers Show How A Modified Pacemaker Strengthens Failing Hearts
Johns Hopkins heart researchers are unraveling the mystery of how a modified pacemaker used to treat many patients with heart failure, known as cardiac resynchronization therapy (CRT), is able to strengthen the heart muscle while making it beat in a coordinated fashion. (Source: Medical Design Online News)
Source: Medical Design Online News - December 10, 2013 Category: Medical Equipment Source Type: news

A modified pacemaker strengthens failing hearts
Johns Hopkins heart researchers are unraveling the mystery of how a modified pacemaker used to treat many patients with heart failure, known as cardiac resynchronization therapy (CRT), is able to strengthen the heart muscle while making it beat in a coordinated fashion. In a new study conducted on animal heart cells described in the Journal of Clinical Investigation, the scientists show that CRT changes these cells so they can contract more forcefully. The researchers also identified an enzyme that mimics this effect of CRT without use of the device. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 3, 2013 Category: Consumer Health News Tags: Heart Disease Source Type: news

Johns Hopkins Researchers Show How a Modified Pacemaker Strengthens Failing Hearts - 12/2/13
Johns Hopkins heart researchers are unraveling the mystery of how a modified pacemaker used to treat many patients with heart failure, known as cardiac resynchronization therapy (CRT), is able to strengthen the heart muscle while making it beat in a coordinated fashion. (Source: Johns Hopkins Medicine News)
Source: Johns Hopkins Medicine News - December 2, 2013 Category: Research Source Type: news

Pacing Strategies and Phrenic Nerve Stimulation in CRTPacing Strategies and Phrenic Nerve Stimulation in CRT
Phrenic nerve stimulation frequently limits cardiac resynchronization therapy delivery. What pacing strategies help to prevent the problem? Journal of Cardiovascular Electrophysiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 14, 2013 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

New Data Published In EP EuroPace Journal Highlights Differences In CRT-ICD Battery Longevity Across Manufacturers
An independent and first-of-its-kind study from theUniversity of PittsburghMedical Center, published online this week inEP EuroPace,shows there are significant differences in battery longevity between contemporary cardiac resynchronization therapy defibrillator (CRT-D) devices, and that the Boston Scientific Corporation (NYSE:BSX) device has the longest battery life compared to competitive brands. (Source: Medical Design Online News)
Source: Medical Design Online News - October 10, 2013 Category: Medical Equipment Source Type: news

FDA Panel Split on Broader Use of CRT
(MedPage Today) -- GAITHERSBURG, Md. -- An FDA advisory panel was less than definitive in its advice on expanding approved use of cardiac resynchronization therapy (CRT) devices for patients with less severe heart failure. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - October 9, 2013 Category: Geriatrics Source Type: news

Following FDA Approval Of Ilesto ICD/CRT-D Devices, BIOTRONIK Launches ILESTO DX
BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced it has received approval from the Food and Drug Administration (FDA) for its Ilesto family of implantable cardioverter-defibrillator/cardiac resynchronization therapy defibrillators (ICD/CRT-D devices). (Source: Medical Design Online News)
Source: Medical Design Online News - October 7, 2013 Category: Medical Equipment Source Type: news

Self-Adjusting CRT Device Cuts Afib in HF (CME/CE)
ORLANDO (MedPage Today) -- A "smart" cardiac resynchronization therapy with defibrillator (CRT-D) device that automatically adjusts pacing to the patient's needs cut incidence of atrial fibrillation in half in heart failure patients, a post hoc analysis found. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 24, 2013 Category: Cardiology Source Type: news

Resynchronization May Be Harmful in Narrow-QRS Heart FailureResynchronization May Be Harmful in Narrow-QRS Heart Failure
QRS width, certainly not echocardiographic dyssynchrony, remains the most effective measure for selecting patients for cardiac resynchronization therapy. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 3, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

ESC: CRT No Help, Maybe Harmful with Short QRS (CME/CE)
AMSTERDAM (MedPage Today) -- Cardiac resynchronization therapy (CRT) might harm patients with moderate-to-severe heart failure who have a low QRS duration, a randomized trial showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 3, 2013 Category: Cardiology Source Type: news

ECHO-CRT: Resynchronization no help, may be harmful in narrow-QRS heart failure
QRS width, certainly not echocardiographic dyssynchrony, remains the most effective measure for selecting patients for cardiac resynchronization therapy. (Source: theHeart.org)
Source: theHeart.org - September 3, 2013 Category: Cardiology Source Type: news

Study Fails To Support Broader Patient Population For Cardiac-Resynchronization Therapy
Cardiac-resynchronization therapy (an advanced feature of pacemakers and ICDs manufactured by Medtronic, Boston Scientific, St. Jude Medical, Biotronik, and Sorin) has been shown to be beneficial in heart failure (HF) patients with a wide QRS interval. These benefits have not been reproduced so far in patients with narrow QRS intervals, though many such patients have ventricular dyssynchrony. Now a new study, presented at the European Society of Cardiology in Amsterdam and published simultaneously in the New England Journal of Medicine, once again has failed to find benefits for CRT in a broader patient populatio...
Source: Forbes.com Healthcare News - September 3, 2013 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

Real-World Use Confirms Bigger CRT Benefits for Some Patients (CME/CE)
(MedPage Today) -- Among Medicare beneficiaries with heart failure, cardiac resynchronization therapy had the greatest impact in those with left bundle-branch block and a longer QRS duration, consistent with clinical trial data, a study showed. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - August 13, 2013 Category: Consumer Health News Source Type: news

Real-World Use Confirms Bigger CRT Benefits for Some (CME/CE)
(MedPage Today) -- Among Medicare beneficiaries with heart failure, cardiac resynchronization therapy had the greatest impact in those with left bundle-branch block and a longer QRS duration, consistent with clinical trial data, a study showed. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - August 13, 2013 Category: Consumer Health News Source Type: news

Study identifies characteristics of heart failure patients more likely to benefit from implantation of cardiac resynchronization device
In a large population of Medicare beneficiaries with heart failure who underwent implantation of a cardiac resynchronization therapy defibrillator, patients who had the cardiac characteristics of left bundle-branch block and longer QRS duration had the lowest risks of death and all-cause, cardiovascular, and heart failure readmission, according to a study in the August 14 issue of JAMA... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 13, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

First ESC Cardiac Pacing And Resynchronization Guidelines Ever To Incorporate A New Section Called 'Clinical Perspectives'
The 2013 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy developed in collaboration with the European Heart Rhythm Association (EHRA), have created a new classification system for bradyarrhythmias according to mechanisms rather than aetiology. The guidelines, presented at the EHRA EUROPACE meeting in Athens, Greece, and published simultaneously in the European Heart Journal and Europace, have been redesigned to offer a more accessible format for users... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 27, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

Practical approach makes new ESC cardiac pacing and resynchronization guidelines accessible to all
(European Society of Cardiology) The 2013 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy have created a new classification system for bradyarrhythmias according to mechanisms rather than aetiology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 25, 2013 Category: Global & Universal Source Type: news

MULIN study challenges widely held assumption that sickest benefit most in CRT
Long term clinical outcome of cardiac resynchronisation therapy (CRT) according to baseline QRS duration:  Cardiac mortality is highest in CRT patients with QRS durations greater than 200 ms, finds the international MULIN study.  MULIN represents the largest study yet to address the relationship between pre-implant QRS duration and long-term outcome for patients undergoing CRT.  Read more  Topics: Arrhythmias (Source: ESC News and Press)
Source: ESC News and Press - June 18, 2013 Category: Cardiology Source Type: news